It’s been a long time since I’ve seen a study suggesting that virtually any part of ACLS really helps cardiac arrest victims, and a recent study in JAMA is no exception. Pretty soon, all we’ll be doing is CPR and defibrillation.
This study is fairly unusual: it’s a randomized, controlled trial of full IV access and meds in cardiac arrest versus no IV access at all. (Patients who had a pulse return could get an IV and any indicated meds.) Previous trials of meds in cardiac arrest have been primarily either RCTs comparing one med to another, or retrospective data on a particular med. Furthermore, this trial looked at survival to discharge as its primary outcome, and neurologically intact survival as a secondary outcome, something that’s been missing in many previous medication trials. (Even the infamous trial that got many people using amiodarone used admission to ICU as its primary outcome, and didn’t look at neurological status at all.) They also reported effects of IV access on CPR quality.
The good news: the study was fairly high quality. IV access didn’t seem to change CPR quality in the group of patients that got it.
The bad news: IV meds don’t seem to do much for the patients. Patients who got them were more likely to have ROSC (particularly in the group of patients with non-shockable rhythms), but were statistically no more likely to be discharged from the hospital (with or without a good neurologic outcome).
Here’s where things get sticky. No medication trial I know of has ever shown any medication to improve survival to good outcome. However, I also don’t know of any that have been able to show harm from medications, either. This study is exactly the same, despite its relatively high quality–it shows no difference between the groups. The problem is that both pro-medication and anti-medication camps will be able to use this study for their arguments.
The anti-medication side will point out the obvious finding: there was no increase in survival with the meds. The pro-medication side will point to several trends that did not reach statistical significance (there was a slight trend towards better survival in the IV group) and claim that a big enough study would make a that difference statistically significant–and that unless we can show a harm from the meds, we should keep using them in case they do have a small helpful effect.
That gets to the heart of the matter: it’s tough to do cardiac arrest research. These researchers picked their study size to show a statistically significant difference only if IV meds doubled survival. That took 851 patients, and getting that number of patients took five years to accumulate. There just isn’t enough research money floating around to have the efforts like some of the cardiology trials that enroll 10,000 patients to show a 1% difference in mortality.
Filed under: EMS Research
No Comments »